Back to top
more

Stryker (SYK)

(Real Time Quote from BATS)

$379.81 USD

379.81
1,478,016

+4.87 (1.30%)

Updated Aug 7, 2025 09:34 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (156 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

athenahealth (ATHN) Beats on Q2 Earnings, Raises '19 View

by Zacks Equity Research

An upbeat 2018 guidance instills investor's optimism for athenahealth (ATHN). However, lackluster performance in the Implementation and other segment is a persistent headwind.

    Zacks Equity Research

    Stryker (SYK) Beats on Q2 Earnings, International Sales Up

    by Zacks Equity Research

    Stryker (SYK) gains from solid segmental performance in Q2.

      Zacks Equity Research

      Here's Why You Should Hold Onto Cardinal Health Stock Now

      by Zacks Equity Research

      Cardinal Health's (CAH) unique portfolio of Medical and Pharmaceutical offerings will lend it a competitive edge in the MedTech space. However, the company faces sluggishness in the exam-gloves unit.

        Mark Vickery headshot

        Top Analyst Reports for Netflix, Eli Lilly & BNY Mellon

        by Mark Vickery

        Today's Research Daily features new research reports on 16 major stocks, including Netflix (NFLX), Eli Lilly (LLY) and BNY Mellon (BK).

          Zacks Equity Research

          Haemonetics Gains on Strong Plasma, Wider Global Footprint

          by Zacks Equity Research

          Strong growth of Haemonetics' (HAE) plasma-derived biopharmaceuticals is attributable to solid end-market demand.

            Zacks Equity Research

            Here's Why You Should Hold Onto Opko Health (OPK) Stock Now

            by Zacks Equity Research

            Opko Health's (OPK) strong focus in R&D bodes well. However, the company faces cutthroat competition in the niche space.

              Zacks Equity Research

              Veeva Systems' Development Cloud Platform Picked by Idorsia

              by Zacks Equity Research

              Switzerland's Idorsia implements Veeva Systems' (VEEV) Development Cloud. Veeva Systems gains foothold in Europe.

                Zacks Equity Research

                Can Rhythm and Neuro Aid Boston Scientific (BSX) Q2 Earnings?

                by Zacks Equity Research

                Boston Scientific (BSX) set to ride high on strength in Rhythm and Neuro business in Q2.

                  Zacks Equity Research

                  Here's Why You Should Add Inogen (INGN) to Your Portfolio

                  by Zacks Equity Research

                  Inogen's (INGN) solid product portfolio is a key catalyst. Also, the company benefits from strong focus in Europe.

                    Zacks Equity Research

                    Here's Why You Should Invest in DaVIta (DVA) Stock Right Now

                    by Zacks Equity Research

                    Strong fundamentals and solid international presence make DaVita (DVA) a lucrative pick.

                      Zacks Equity Research

                      QIAGEN Test-Menu Expansion on Track, Low HPV Sales a Woe

                      by Zacks Equity Research

                      QIAGEN's (QGEN) HPV sales in the United States remain tepid. Weak APAC sales are due to bleak applied testing business.

                        Zacks Equity Research

                        Boston Scientific (BSX) Q2 Earnings: Is a Beat in Store?

                        by Zacks Equity Research

                        Boston Scientific (BSX) expects to consistently gain from impressive growth across all business lines and geographies.

                          Zacks Equity Research

                          Here's Why You Should Add Edwards Lifesciences (EW) Now

                          by Zacks Equity Research

                          We are upbeat about Edwards Lifesciences' (EW) strong transcatheter valve sales in the domestic market as well as overseas.

                            Zacks Equity Research

                            Here's Why You Should Invest in BioScrip (BIOS) Right Now

                            by Zacks Equity Research

                            We are upbeat about BioScrip's (BIOS) progress in the last reported quarter, courtesy of its multi-faceted CORE plan to improve financial position.

                              Zacks Equity Research

                              Will 5 Elements Drive Quest Diagnostics (DGX) Q2 Earnings?

                              by Zacks Equity Research

                              Per Quest Diagnostics (DGX), growing strength of partnerships with health care leaders and strategic acquisitions are creating growth prospects for the top and bottom-line growth.

                                Zacks Equity Research

                                Can Established Pharmaceuticals Up Abbott (ABT) Q2 Earnings?

                                by Zacks Equity Research

                                According to Abbott (ABT), key emerging markets represent the most attractive long-term growth opportunities for its branded generics product portfolio within EPD.

                                  Zacks Equity Research

                                  Can Medical Devices Strength Drive Abbott (ABT) Q2 Earnings?

                                  by Zacks Equity Research

                                  Abbott (ABT) poised to gain on continued growth in Medical Devices business in Q2.

                                    Zacks Equity Research

                                    Can Abbott (ABT) Rise on Robust Overall Growth in Q2 Earnings?

                                    by Zacks Equity Research

                                    Abbott (ABT) gains traction from a steady healthy growth trajectory seen in core Diabetes Care business.

                                      Zacks Equity Research

                                      Here's Why You Should Hold Intuitive Surgical (ISRG) Stock

                                      by Zacks Equity Research

                                      Strong performance by Intuitive Surgical's (ISRG) flagship da Vinci system is a key growth driver. However, the company faces stiff competition in the niche space.

                                        Zacks Equity Research

                                        BD Buys TVA Medical, To Provide Minimally Invasive Procedure

                                        by Zacks Equity Research

                                        The acquisition of TVA Medical will enable Becton, Dickinson (BDX) to treat patients with chronic kidney disease through minimally invasive procedures.

                                          Zacks Equity Research

                                          Why You Should Add Boston Scientific (BSX) to Your Portfolio

                                          by Zacks Equity Research

                                          Boston Scientific's (BSX) agreement for Cryterion Medical buyout in the field of atrial fibrillation buoys investor optimism on the stock.

                                            Zacks Equity Research

                                            Medtronic (MDT) Rides on Innovation, Rising Costs a Woe

                                            by Zacks Equity Research

                                            Medtronic (MDT) continues to meaningfully accelerate all its three fundamental growth strategies, namely therapy innovation, globalization and economic value.

                                              Zacks Equity Research

                                              Intuitive Surgical's FDA Approval for SureForm to Aid Surgery

                                              by Zacks Equity Research

                                              Intuitive Surgical's (ISRG) SureForm 60 stapler receives FDA approval; strengthens its profile for minimally invasive surgical solutions.

                                                Zacks Equity Research

                                                Will Core Segmental Growth Aid Stryker (SYK) in Q2 Earnings?

                                                by Zacks Equity Research

                                                Stryker's (SYK) strong segmental performance and acquisition-driven strategy are likely to drive Q2 earnings.

                                                  Zacks Equity Research

                                                  Walgreens Boots (WBA) Grows on New Pacts Amid Several Woes

                                                  by Zacks Equity Research

                                                  Walgreens Boots' (WBA) alliance with Express Scripts is expected to expand both companies' existing group purchasing efforts.